Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) was submitted on April 9, 2026, reporting an event that occurred on April 8, 2026. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding the Company's stock price.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq staff indicating that the Company's common stock failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days (February 24, 2026, through April 7, 2026). This deficiency violates Nasdaq Listing Rule 5450(a)(1).
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending on October 5, 2026, to regain compliance.
- Requirements: To comply, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the compliance date.
- Secondary Options: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period. This would require transferring its listing to the Nasdaq Capital Market and meeting other listing standards, potentially via a reverse stock split.
- Risks: There is no assurance the Company will regain compliance or that an appeal of a potential delisting determination would be successful. Immediate delisting is not occurring, but the risk of future delisting exists if the deficiency is not cured.
Investor Verification Checklist
- Verify the current trading price of GOSS to assess the likelihood of meeting the $1.00 minimum bid price requirement.
- Monitor Company announcements for any proposed reverse stock split or other capital structure changes intended to cure the deficiency.
- Review the Company's cash position and liquidity in subsequent filings (10-Q or 10-K) to understand the financial drivers behind the low stock price.
- Track the status of the compliance period to ensure the Company meets the October 5, 2026, deadline or successfully applies for an extension.